Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Autolus Therapeutics Plc
A London-based biotech that engineers living immune cells called CAR-T cells into "living drugs" to fight blood cancers. Its lead therapy, marketed as Aucatzyl, treats adults with a hard-to-treat form of acute lymphoblastic leukemia. The company spun out of University College London in 2011, and its name comes from the Greek word "autos" ("self"), reflecting how it reprograms a patient's own cells to attack their cancer.
American Depositary Receipts (Sponsored ADR)
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 3.02 Unregistered Sales of Equity Securities · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
8.01 Other Events
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
2.05 Costs Associated with Exit or Disposal Activities · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
4.01 Changes in Registrant's Certifying Accountant · 9.01 Financial Statements and Exhibits